Sands Capital Ventures
Edit

Sands Capital Ventures

https://www.sandscapital.com/
Last activity: 14.05.2024
Active
Every aspect of the Sands Capital culture is geared toward delivering strong results for our clients.
Portfolio
1
Mentions
34

Portfolio 1

DateNameWebsiteTotal RaisedLocation
21.10.2022Telliustellius.com$31.5MUnited Sta...

Mentions in press and media 34

DateTitleDescription
14.05.2024Sands Capital wraps up third life sciences fund at $555m-
18.04.2024Ramp's Rise: A Financial FrenzyRamp, the financial automation platform, has secured a whopping $150 million in Series D-2 funding, co-led by Khosla Ventures and Founders Fund. This injection of cash has catapulted Ramp's valuation to a staggering $7.65 billion, solidifyi...
17.04.2024Ramp raises another $150M co-led by Khosla and Founders Fund at a $7.65B valuationSpend management startup Ramp has raised another $150 million at a post-money valuation of $7.65 billion, the company confirmed to TechCrunch today. New investor Khosla Ventures and existing backer Founders Fund co-led the raise, which also...
19.03.2024JumpCloud Acquires ResmoJumpCloud, a Louisville CO-based company helping IT teams and managed service providers, acquired Resmo, a Dover, Delaware-based provider asset management and SaaS security solution for modern, cloud-native IT and SecOps teams. The amount o...
12.03.2024Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s DiseaseNAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative disease...
12.03.2024Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease-Following positive pre-submission meetings with regulators, Prilenia plans to submit its MAA for pridopidine in Huntington’s disease (HD) in mid-2024- -If approved, pridopidine could be commercially available to patients in Europe as early...
28.02.2024Alamar Biosciences: Revolutionizing Precision ProteomicsAlamar Biosciences, a Fremont-based company, recently secured $128M in Series C funding to advance their innovative precision proteomics platform. Led by Sands Capital, this funding round will propel the company's mission to enable early di...
27.02.2024Freenome scores $254M to advance its cancer-detection blood testsThe San Francisco company readies to reveal its first clinical study results in the near term When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un...
26.02.2024Alamar Biosciences Raises $128M to Accelerate Proteomics PlatformWhat You Should Know: – Alamar Biosciences, a leader in precision proteomics for early disease detection raises $100M in Series C round, with an additional $28M expected within the next 30 days. This brings their total funding to nearly $25...
22.02.2024HealthSnap Revolutionizes Chronic Care ManagementHealthSnap, a Miami-based provider of remote patient monitoring and chronic care management solutions, recently secured $25M in Series B funding. Led by Sands Capital, this funding round positions HealthSnap for continued growth and innovat...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In